Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Simply Wall St.08-10

Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658931753?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-08-10 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658931753","market":"nz","top_or_hot":-1,"title":"Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data","media":"Simply Wall St.","content":"<div>\n<p>Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-is-down-71-after-advancing-pcrx-201\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-10 20:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-is-down-71-after-advancing-pcrx-201><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-is-down-71-after-advancing-pcrx-201\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-is-down-71-after-advancing-pcrx-201","article_id":"2658931753","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/pacira-biosciences-pcrx-is-down-71-after-advancing-pcrx-201","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2658931753","pubTimestamp":1786365108,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well tolerated and associated with improvements in pain, stiffness, and function, and incorporated glucocorticoid pretreatment into its ongoing Phase 2 ASCEND study following favorable safety findings.\nBy pairing encouraging long-term clinical data with a successful transition to scalable U.S.-based...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PCRX":"Pacira Pharmaceuticals"},"translate_title":"Pacira BioSciences (PCRX) 在推进 PCRX-201 基因疗法并取得积极的 1 期数据后下跌 7.1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":1.5},"content_text":"Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well tolerated and associated with improvements in pain, stiffness, and function, and incorporated glucocorticoid pretreatment into its ongoing Phase 2 ASCEND study following favorable safety findings. By pairing encouraging long-term clinical data with a successful transition to scalable U.S.-based manufacturing and RMAT/ATMP regulatory designations, Pacira has moved PCRX-201 closer to potential late-stage development in a disease that affects more than 15 million people in the U.S. alone. We’ll now examine how the advancement of PCRX-201 into scalable Phase 2 manufacturing and enrollment could reshape Pacira BioSciences’ investment narrative. Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.AdvertisementPacira BioSciences Investment Narrative RecapTo own Pacira, you have to believe its non opioid pain franchise can keep funding a gradual shift toward a more diversified, gene therapy enabled business. The new PCRX 201 data and Phase 2 progress strengthen the case for that pivot, but the key near term catalyst remains ASCEND Part A topline results by year end 2026, while the biggest risk is still execution and spend on a pipeline that may not translate into approved, revenue generating products. Among recent announcements, the update on 2026 guidance and Q2 results is especially relevant. Pacira modestly lowered full year revenue expectations to US$735 million to US$760 million even as it reported US$192.4 million in Q2 revenue and a swing to profitability, underscoring that pipeline investment, including PCRX 201, must be balanced against near term growth and margin pressures. Yet behind the promise of PCRX 201, investors should also be aware of the risk that... Read the full narrative on Pacira BioSciences (it's free!)Pacira BioSciences’ narrative projects $908.9 million revenue and $112.0 million earnings by 2028.Uncover how Pacira BioSciences' forecasts yield a $29.00 fair value, a 16% upside to its current price.Exploring Other PerspectivesPCRX 1-Year Stock Price Chart Some of the lowest estimate analysts were already cautious, assuming revenue of about US$865 million and earnings of roughly US$97 million by 2029, and their view of PCRX 201 and the HCAd platform as diversification upside contrasts sharply with the consensus focus on EXPAREL risk, which this new gene therapy update could cause both camps to reassess.Explore 3 other fair value estimates on Pacira BioSciences - why the stock might be a potential multi-bagger!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Pacira BioSciences research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Pacira BioSciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pacira BioSciences' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Opportunities like this don't last. These are today's most promising picks. Check them out now:Find 52 companies with promising cash flow potential yet trading below their fair value.We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658931753","isCrawlerRequest":true}